{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/prescribing-information/trimethoprim/","result":{"pageContext":{"chapter":{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim","depth":2,"htmlHeader":"<!-- begin field 5ab155a6-1aaf-4613-9347-a99e00e41a6f --><h2>Trimethoprim</h2><!-- end field 5ab155a6-1aaf-4613-9347-a99e00e41a6f -->","summary":"","htmlStringContent":"<!-- begin item 501019db-cd1b-4d0e-b382-a99e00e419e6 --><!-- end item 501019db-cd1b-4d0e-b382-a99e00e419e6 -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"af3c0195-7d54-5f62-aee1-0f119f756f95","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e127e06c-8259-4c22-8098-a99e00e43b8e --><h3>Contraindications and cautions</h3><!-- end field e127e06c-8259-4c22-8098-a99e00e43b8e -->","summary":"","htmlStringContent":"<!-- begin item fab78e31-36d3-4b1b-b395-a99e00e43b3d --><!-- begin field 62a1e88f-eb02-4a86-876c-a99e00e43b8e --><ul><li><strong>Do not prescribe trimethoprim in:</strong><ul><li>People with severe hepatic insufficiency, or severe renal insufficiency.</li><li>People with megaloblastic anaemia or other blood dyscrasias.</li><li>Premature infants or children aged under 4 months.</li><li>Women who are pregnant.</li></ul></li><li><strong>Prescribe trimethoprim with caution in people:</strong><ul><li>With impaired renal function.</li><li>With hyperkalaemia, or taking medication that is known to cause hyperkalaemia.</li><li>With acute porphyria.</li><li>Predisposed to folate deficiency — because of the potential anti-folate effect of trimethoprim, there is a risk of further exacerbating folate deficiency in people who are folate deficient, or who are predisposed to folate deficiency (for example elderly people), or who are taking folate antagonists.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 62a1e88f-eb02-4a86-876c-a99e00e43b8e --><!-- end item fab78e31-36d3-4b1b-b395-a99e00e43b3d -->","subChapters":[]},{"id":"924eeaa7-b53e-5ad0-9624-4ea9c9de64c3","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1501c9a1-428b-4acb-831c-a99e00e4530c --><h3>Adverse effects</h3><!-- end field 1501c9a1-428b-4acb-831c-a99e00e4530c -->","summary":"","htmlStringContent":"<!-- begin item 5393ffb8-9330-4125-b87d-a99e00e452d7 --><!-- begin field cf61614c-4516-49c3-ae14-a99e00e4530c --><ul><li><strong>Blood disorders</strong> — leukopenia, megaloblastic anaemia, thrombocytopenia, agranulocytosis, hyperkalaemia (particularly in the elderly and in HIV patients), methaemoglobinaemia.</li><li><strong>Gastrointestina</strong>l — nausea, diarrhoea, vomiting (common). </li><li><strong>Nervous system</strong> — aseptic meningitis (frequency unknown).</li><li><strong>Skin</strong> — Pruritus, and skin rashes (common).<ul><li><strong>Rarely: </strong>Photosensitivity, exfoliative dermatitis, fixed drug eruption, erythema multiforme, erythema nodusum, Stevens-Johnson Syndrome, toxic epidermal necrolysis, bullous dermatitis, purpura, angioedema.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Liver enzyme disturbances, cholestatic jaundice.</li><li>Myalgia.</li><li>Raised serum creatinine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field cf61614c-4516-49c3-ae14-a99e00e4530c --><!-- end item 5393ffb8-9330-4125-b87d-a99e00e452d7 -->","subChapters":[]},{"id":"8adfb518-ace9-5c55-ab90-3cb8efb05d75","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ed430315-cbbe-4244-8dfd-a99e00e4625c --><h3>Drug interactions</h3><!-- end field ed430315-cbbe-4244-8dfd-a99e00e4625c -->","summary":"","htmlStringContent":"<!-- begin item 6593d466-3265-48ce-a6be-a99e00e46226 --><!-- begin field b1050e20-c36d-46cf-b581-a99e00e4625c --><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors and </strong><strong>angiotensin-II receptor antagonists </strong><strong>AIIRAs</strong> — there may be an increased risk of hyperkalaemia with the concurrent use of these drugs and trimethoprim. Monitor potassium concentrations. </li><li><strong>Azathioprine and mercaptopurine </strong>— <strong> </strong>increased risk of haematological toxicity in people who have had a renal transplant. However, the combination is commonly used in practice. Monitor the full blood count routinely.</li><li><strong>Ciclosporin </strong>— serum creatinine levels may be increased. Possible increased risk of nephrotoxicity. Monitor renal function closely.</li><li><strong>Coumarins (warfarin) </strong>—  the anticoagulant effect of coumarins may be potentiated. Monitor international normalised ratio (INR) and adjust dose accordingly.</li><li><strong>Digoxin</strong> — digoxin levels may be increased in the elderly if taken with trimethoprim. Monitor for digoxin adverse effects, and adjust dose accordingly.</li><li><strong>Diuretics </strong>—  hyperkalaemia may be exacerbated by concomitant administration of diuretics, particularly potassium sparing diuretics and/or thiazide diuretics and eplerenone.</li><li><strong>Methotrexate (a folate antagonist) </strong>— there is an increased risk of haematologic adverse effects. Several cases of bone marrow suppression have been reported (some fatal). Full blood count should be monitored routinely.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of trimethoprim.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li><li><strong>Phenytoin </strong>— phenytoin levels may be increased if taken with trimethoprim. Monitor phenytoin levels and adjust dose accordingly</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field b1050e20-c36d-46cf-b581-a99e00e4625c --><!-- end item 6593d466-3265-48ce-a6be-a99e00e46226 -->","subChapters":[]},{"id":"4f54f8ff-1e47-5758-b19e-5b126925c1fe","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 522c7155-a0cf-44bc-9dd3-a99e00e479cc --><h3>Pregnancy and breastfeeding</h3><!-- end field 522c7155-a0cf-44bc-9dd3-a99e00e479cc -->","summary":"","htmlStringContent":"<!-- begin item 456cacc8-217f-4760-a69e-a99e00e4798b --><!-- begin field b93f9cd9-2046-429c-86fd-a99e00e479cc --><ul><li><strong>Pregnancy</strong><ul><li>There is a teratogenic risk in the first trimester of pregnancy. The manufacturer advises that it should not be used in women who are pregnant.</li><li>In women with normal folate status, who are well nourished, use of trimethoprim for a short period is unlikely to induce folate deficiency, however, it should be avoided if folate deficiency is suspected.</li><li>If trimethoprim is recommended for use during the first trimester:<ul><li>Ensure the woman is taking a folic acid supplement.</li><li>Prescribe folic acid 5 mg daily.</li></ul></li></ul></li><li><strong>Breastfeeding</strong><ul><li>Trimethoprim is excreted in breastmilk, but is not known to be harmful.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">NPIS, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field b93f9cd9-2046-429c-86fd-a99e00e479cc --><!-- end item 456cacc8-217f-4760-a69e-a99e00e4798b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}